← Eichor
Study identifier: NCT05461820 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Condition: Graves Disease · Relapse · Treatment  ·  Sponsor: The First Affiliated Hospital with Nanjing Medical University

PhasePhase 4
Planned participants240
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.

This description comes directly from the study's public registry record.

Talk to the study team

Xuqin Zheng  ·  13912902902  ·  zhengxuqin@njmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

the First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05461820